Piramal Healthcare To Buy Molecular Imaging Research Portfolio of Bayer

Fox Business Sunday 15th April, 2012

BANGALORE – Piramal Healthcare Ltd. (500302.BY) said Monday it has agreed to acquire the global rights to the molecular imaging research and development portfolio of Bayer AG (BAYN.XE) for an undisclosed amount.The portfolio includes rights to florbetaben, a radioactive compound being developed by Bayer to diagnose Alzheimer's disease, the Indian company said in a statement.Piramal Healthcare will get the intellectual property, worldwide de...

Read more

Share this article:
Back to Toronto Telegraph

Comments

  • No comments yet for this story

    • Have your say

    • By submitting your comment you agree to our terms and conditions

    Featured Story

    One-billion-year-old water ' saltier than seawater'

    University of Toronto scientists have found pockets of water that had been sitting 2.4 kilometres underneath the Earth's surface for more than a billion years.

    Earth sciences professor Barbara Sherwood, ...

    Record Your Vote

    Should tax havens be forced to lift their shroud of secrecy?

    View results

    On Facebook

    Reported in the press

    Our nuclear programmes are completely transparent. But we are ready to show greater transparency and make clear for the whole world that the steps of the Islamic Republic of Iran are completely within international frameworks. The sanctions are unfair, the Iranian people are suffering, and our (nuclear) activities are legal. These sanctions are illegal and only benefit Israel.

    Hassan Rouhani

    Iran's president-elect was speaking after his historic election victory.